Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89


Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espié M, Benchimol G, Laas E, Laé M, Asselain B, Aouchiche B, Edelman M, Reyal F.

J Clin Oncol. 2019 Mar 10;37(8):624-635. doi: 10.1200/JCO.18.00636. Epub 2019 Jan 31.


Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer.

Innominato PF, Komarzynski S, Palesh OG, Dallmann R, Bjarnason GA, Giacchetti S, Ulusakarya A, Bouchahda M, Haydar M, Ballesta A, Karaboué A, Wreglesworth NI, Spiegel D, Lévi FA.

Cancer Med. 2018 Sep;7(9):4396-4405. doi: 10.1002/cam4.1711. Epub 2018 Aug 7.


Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison.

Ruiz A, van Hillegersberg R, Siesling S, Castro-Benitez C, Sebagh M, Wicherts DA, de Ligt KM, Goense L, Giacchetti S, Castaing D, Morère J, Adam R.

Eur J Cancer. 2018 May;95:1-10. doi: 10.1016/j.ejca.2018.02.024. Epub 2018 Mar 23.


COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.


The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus.

Ozturk N, Ozturk D, Pala-Kara Z, Kaptan E, Sancar-Bas S, Ozsoy N, Cinar S, Deniz G, Li XM, Giacchetti S, Lévi F, Okyar A.

Chronobiol Int. 2018 May;35(5):705-718. doi: 10.1080/07420528.2018.1432632. Epub 2018 Feb 5.


Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock.

Zhang Y, Giacchetti S, Parouchev A, Hadadi E, Li X, Dallmann R, Xandri-Monje H, Portier L, Adam R, Lévi F, Dulong S, Chang Y.

Cell Cycle. 2018;17(1):33-42. doi: 10.1080/15384101.2017.1387695. Epub 2018 Jan 2.


Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.

Bousquet G, El Bouchtaoui M, Sophie T, Leboeuf C, de Bazelaire C, Ratajczak P, Giacchetti S, de Roquancourt A, Bertheau P, Verneuil L, Feugeas JP, Espié M, Janin A.

Oncotarget. 2017 May 23;8(21):35205-35221. doi: 10.18632/oncotarget.16925.


Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.


Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results.

Ruiz A, Wicherts DA, Sebagh M, Giacchetti S, Castro-Benitez C, van Hillegersberg R, Paule B, Castaing D, Morère JF, Adam R.

Ann Surg Oncol. 2017 Feb;24(2):535-545. doi: 10.1245/s10434-016-5522-7. Epub 2016 Aug 29.


[Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].

Cochereau D, Da Costa S, Le Maignan C, Gauthier H, Cochereau J, Espié M, Giacchetti S, Teixeira L.

Bull Cancer. 2016 May;103(5):444-54. doi: 10.1016/j.bulcan.2016.02.002. Epub 2016 Mar 15. French.


Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies.

Hamy AS, Porcher R, Eskenazi S, Cuvier C, Giacchetti S, Coussy F, Hocini H, Tournant B, Perret F, Bonfils S, Charvériat P, Lacorte JM, Espie M.

Reprod Biomed Online. 2016 Mar;32(3):299-307. doi: 10.1016/j.rbmo.2015.12.008. Epub 2016 Jan 6.


¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.

Groheux D, Biard L, Giacchetti S, Teixeira L, Hindié E, Cuvier C, Vercellino L, Merlet P, de Roquancourt A, de Cremoux P, Resche-Rigon M, Espié M.

J Nucl Med. 2016 Apr;57(4):536-43. doi: 10.2967/jnumed.115.163907. Epub 2015 Dec 23.


Ductal carcinoma in situ (DCIS) treated by mastectomy, or local excision with or without radiotherapy: A monocentric, retrospective study of 608 women.

Frank S, Dupont A, Teixeira L, Porcher R, De Roquancourt A, Giacchetti S, Espié M, Cuvier C.

Breast. 2016 Feb;25:51-6. doi: 10.1016/j.breast.2015.10.008. Epub 2015 Nov 10.


Repeat Hepatectomy for Breast Cancer Liver Metastases.

Ruiz A, Castro-Benitez C, Sebagh M, Giacchetti S, Castro-Santa E, Wicherts DA, van Hillegersberg R, Paule B, Castaing D, Morère JF, Adam R.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1057-66. doi: 10.1245/s10434-015-4785-8. Epub 2015 Aug 11.


Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.

Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M.

Radiology. 2015 Nov;277(2):358-71. doi: 10.1148/radiol.2015141638. Epub 2015 Apr 27.


Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E.

J Nucl Med. 2015 Jun;56(6):824-31. doi: 10.2967/jnumed.115.154138. Epub 2015 Apr 16.


Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis.

Nikpayam M, Uzan C, Rivera S, Delaloge S, Cahen-Doidy L, Giacchetti S, Espié M, Groheux D.

Anticancer Res. 2015 Mar;35(3):1729-34.


Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer.

Innominato PF, Spiegel D, Ulusakarya A, Giacchetti S, Bjarnason GA, Lévi F, Palesh O.

Sleep Med. 2015 Mar;16(3):391-8. doi: 10.1016/j.sleep.2014.10.022. Epub 2015 Jan 22.


[New targeted therapies in breast cancer].

Coussy F, Teixeira L, Giacchetti S, Cuvier C, Hocini H, Espié M.

Gynecol Obstet Fertil. 2014 Nov;42(11):787-94. doi: 10.1016/j.gyobfe.2014.09.007. Epub 2014 Oct 19. Review. French.


Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.

Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, Espié M, Hindié E.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):377-85. doi: 10.1007/s00259-014-2941-1. Epub 2014 Nov 29.


Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.

Hamy AS, Porcher R, Cuvier C, Giacchetti S, Schlageter MH, Coussieu C, Gronier H, Feugeas JP, Adoui N, Lacorte JM, Poirot C, Habdous M, Espié M.

Reprod Biomed Online. 2014 Nov;29(5):573-80. doi: 10.1016/j.rbmo.2014.07.008. Epub 2014 Jul 28.


Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival.

Lévi F, Dugué PA, Innominato P, Karaboué A, Dispersyn G, Parganiha A, Giacchetti S, Moreau T, Focan C, Waterhouse J, Spiegel D; ARTBC Chronotherapy Group.

Chronobiol Int. 2014 Oct;31(8):891-900. doi: 10.3109/07420528.2014.924523. Epub 2014 Jun 13.


Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M.

Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16.


Contraception after breast cancer: a retrospective review of the practice among French gynecologists in the 2000's.

Hamy AS, Abuellellah H, Hocini H, Coussy F, Gorins A, Serfaty D, Tournant B, Perret F, Bonfils S, Giacchetti S, Cuvier C, Espie M.

Eur J Gynaecol Oncol. 2014;35(2):149-53.


Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.

Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M.

Br J Cancer. 2014 Mar 18;110(6):1413-9. doi: 10.1038/bjc.2014.81. Epub 2014 Feb 25.


Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B.

Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2.


p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.


HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.

Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, Cuvier C, Coussy F, Espié M, Hindié E.

Br J Cancer. 2013 Sep 3;109(5):1157-64. doi: 10.1038/bjc.2013.469. Epub 2013 Aug 13.


Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study.

Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, Alran S, Giacchetti S, Marty M, Lebofsky R, Pierga JY.

Int J Breast Cancer. 2013;2013:130470. doi: 10.1155/2013/130470. Epub 2013 May 9.


Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, de Bazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, Espié M, de Thé H, Bertheau P.

Breast Cancer Res. 2013 May 11;15(3):R37. doi: 10.1186/bcr3421.


Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.

Richard R, Thomassin I, Chapellier M, Scemama A, de Cremoux P, Varna M, Giacchetti S, Espié M, de Kerviler E, de Bazelaire C.

Eur Radiol. 2013 Sep;23(9):2420-31. doi: 10.1007/s00330-013-2850-x. Epub 2013 May 8.


Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.

Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Poncet A, Spiegel D, Lévi F; International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group.

Cancer. 2013 Jul 15;119(14):2564-73. doi: 10.1002/cncr.28072. Epub 2013 Apr 30.


Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.

Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15.


Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.

Hatt M, Groheux D, Martineau A, Espié M, Hindié E, Giacchetti S, de Roquancourt A, Visvikis D, Cheze-Le Rest C.

J Nucl Med. 2013 Mar;54(3):341-9. doi: 10.2967/jnumed.112.108837. Epub 2013 Jan 17.


Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert ME, Merlet P, Espié M.

J Natl Cancer Inst. 2012 Dec 19;104(24):1879-87. doi: 10.1093/jnci/djs451. Epub 2012 Dec 12.


Performance of FDG PET/CT in the clinical management of breast cancer.

Groheux D, Espié M, Giacchetti S, Hindié E.

Radiology. 2013 Feb;266(2):388-405. doi: 10.1148/radiol.12110853. Epub 2012 Dec 6. Review.


18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.

Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espié M.

J Nucl Med. 2013 Jan;54(1):5-11. doi: 10.2967/jnumed.112.106864. Epub 2012 Dec 4.


Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Lévi F; ARTBC International Chronotherapy Group.

Ann Oncol. 2012 Dec;23(12):3110-6. doi: 10.1093/annonc/mds148. Epub 2012 Jun 27.


Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.

Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, Iacobelli S, Tampellini M, Durando X, Mormont MC, Waterhouse J, Lévi FA.

Int J Cancer. 2012 Dec 1;131(11):2684-92. doi: 10.1002/ijc.27574. Epub 2012 Jul 3.


Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.

Groheux D, Hindié E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, Vercellino L, Berenger N, Marty M, Espié M.

J Nucl Med. 2012 Feb;53(2):249-54. doi: 10.2967/jnumed.111.094045. Epub 2012 Jan 12.


The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.

Groheux D, Giacchetti S, Espié M, Vercellino L, Hamy AS, Delord M, Berenger N, Toubert ME, Misset JL, Hindié E.

J Nucl Med. 2011 Oct;52(10):1526-34. doi: 10.2967/jnumed.111.093864. Epub 2011 Aug 30.


Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).

Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Lévi F; ARTBC International Chronotherapy Group.

Chronobiol Int. 2011 Aug;28(7):586-600. doi: 10.3109/07420528.2011.597532.


BI-RADS categorisation of 2,708 consecutive nonpalpable breast lesions in patients referred to a dedicated breast care unit.

Hamy AS, Giacchetti S, Albiter M, de Bazelaire C, Cuvier C, Perret F, Bonfils S, Charvériat P, Hocini H, de Roquancourt A, Espie M.

Eur Radiol. 2012 Jan;22(1):9-17. doi: 10.1007/s00330-011-2201-8. Epub 2011 Jul 16.


Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa LF, Giacchetti S, Espié M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de Thé H, Bertheau P.

Br J Cancer. 2011 May 24;104(11):1739-46. doi: 10.1038/bjc.2011.135. Epub 2011 May 3.


Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients.

Reyal F, Valet F, de Cremoux P, Mathiot C, Decraene C, Asselain B, Brain E, Delaloge S, Giacchetti S, Marty M, Pierga JY, Bidard FC.

Ann Oncol. 2011 Jun;22(6):1458-9. doi: 10.1093/annonc/mdr144. Epub 2011 Apr 27. No abstract available.


Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.

Groheux D, Giacchetti S, Espié M, Rubello D, Moretti JL, Hindié E.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):419-25. doi: 10.1007/s00259-010-1660-5. No abstract available.


Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):426-35. doi: 10.1007/s00259-010-1640-9. Epub 2010 Nov 6.


Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.

Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, Giacchetti S, Guettier C, Azoulay D, Castaing D, Adam R.

Ann Surg Oncol. 2011 Mar;18(3):659-69. doi: 10.1245/s10434-010-1385-5. Epub 2010 Oct 26.


Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.

Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M.

Cancer Chemother Pharmacol. 2011 Feb;67(2):339-48. doi: 10.1007/s00280-010-1327-8. Epub 2010 Apr 17.


The evolving role of PET/CT in breast cancer.

Groheux D, Giacchetti S, Rubello D, Al-Nahhas A, Moretti JL, Espié M, Hindié E.

Nucl Med Commun. 2010 Apr;31(4):271-3. doi: 10.1097/MNM.0b013e3283354cb4. No abstract available.


Supplemental Content

Loading ...
Support Center